Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care - PubMed
3 days ago
- #metastatic breast cancer
- #CDK4/6 inhibitors
- #real-world evidence
- CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) combined with aromatase inhibitors (AI) are first-line treatments for hormone receptor-positive/HER2-negative metastatic breast cancer (mBC).
- Target trial emulation framework was used to compare overall survival (OS) among CDK4/6 inhibitors in real-world settings, addressing biases and confounders.
- Study included 2,626 patients treated between 2018-2024, with balanced baseline characteristics after statistical adjustments (sIPTW).
- No significant difference in OS was found between palbociclib, ribociclib, and abemaciclib when combined with AI (adjusted hazard ratios close to 1).
- Results support similar effectiveness of CDK4/6 inhibitors in routine care, aiding clinical decision-making and future combination strategies.